CIK 0001781983 · Non-accelerated filer<br>Smaller reporting company
Aprea Therapeutics, Inc.
Sign in to watch- Ticker
- APRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 215-948-4119
- Business address
- 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 52 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-18 | Duey Marc Director | Sale | −6,462 | $4.58 | $30K | 233,651 |
| 2022-02-28 | Attar Eyal C. SVP, Chief Medical Officer | Sale | −36,000 | $1.73 | $62K | 47,000 |
| 2021-12-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $3.96 | $109K | 17,167 |
| 2021-11-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $5.00 | $138K | 17,167 |
| 2021-10-01 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Sale | −50,000 | $4.89 | $245K | 19,000 |
| 2021-10-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $4.89 | $134K | 17,167 |
| 2021-09-20 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −5,460 | $4.98 | $27K | 17,167 |
| 2021-09-20 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $4.97 | $137K | 17,167 |
| 2021-09-20 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Sale | −25,000 | $4.97 | $124K | 19,000 |
| 2021-09-16 | Attar Eyal C. SVP, Chief Medical Officer | Sale | −15,968 | $4.68 | $75K | 83,000 |
Page 1 of 1 · 10 trades